rs141251993
Positions:
Variant summary
Our verdict is Benign. Variant got -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BS1BS2
The NM_178012.5(TUBB2B):c.330C>T(p.Ala110Ala) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00711 in 1,613,012 control chromosomes in the GnomAD database, including 71 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Genomes: 𝑓 0.0056 ( 5 hom., cov: 31)
Exomes 𝑓: 0.0073 ( 66 hom. )
Consequence
TUBB2B
NM_178012.5 synonymous
NM_178012.5 synonymous
Scores
2
Clinical Significance
Conservation
PhyloP100: -2.48
Genes affected
TUBB2B (HGNC:30829): (tubulin beta 2B class IIb) The protein encoded by this gene is a beta isoform of tubulin, which binds GTP and is a major component of microtubules. This gene is highly similar to TUBB2A and TUBB2C. Defects in this gene are a cause of asymmetric polymicrogyria. [provided by RefSeq, Mar 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -21 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.78).
BP6
Variant 6-3225759-G-A is Benign according to our data. Variant chr6-3225759-G-A is described in ClinVar as [Likely_benign]. Clinvar id is 160180.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr6-3225759-G-A is described in Lovd as [Likely_benign].
BP7
Synonymous conserved (PhyloP=-2.48 with no splicing effect.
BS1
Variant frequency is greater than expected in population sas. gnomad4 allele frequency = 0.00565 (859/152060) while in subpopulation SAS AF= 0.00958 (46/4800). AF 95% confidence interval is 0.00738. There are 5 homozygotes in gnomad4. There are 417 alleles in male gnomad4 subpopulation. Median coverage is 31. This position pass quality control queck.
BS2
High AC in GnomAd4 at 859 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TUBB2B | NM_178012.5 | c.330C>T | p.Ala110Ala | synonymous_variant | 4/4 | ENST00000259818.8 | NP_821080.1 |
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00564 AC: 857AN: 151942Hom.: 5 Cov.: 31
GnomAD3 genomes
AF:
AC:
857
AN:
151942
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00747 AC: 1853AN: 248162Hom.: 5 AF XY: 0.00800 AC XY: 1079AN XY: 134904
GnomAD3 exomes
AF:
AC:
1853
AN:
248162
Hom.:
AF XY:
AC XY:
1079
AN XY:
134904
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00726 AC: 10607AN: 1460952Hom.: 66 Cov.: 34 AF XY: 0.00761 AC XY: 5531AN XY: 726734
GnomAD4 exome
AF:
AC:
10607
AN:
1460952
Hom.:
Cov.:
34
AF XY:
AC XY:
5531
AN XY:
726734
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00565 AC: 859AN: 152060Hom.: 5 Cov.: 31 AF XY: 0.00561 AC XY: 417AN XY: 74324
GnomAD4 genome
AF:
AC:
859
AN:
152060
Hom.:
Cov.:
31
AF XY:
AC XY:
417
AN XY:
74324
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Benign/Likely benign
Submissions summary: Benign:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Benign:3
Benign, criteria provided, single submitter | clinical testing | GeneDx | Feb 14, 2018 | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. - |
Likely benign, criteria provided, single submitter | clinical testing | Genetic Services Laboratory, University of Chicago | Aug 19, 2013 | - - |
Benign, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jun 24, 2015 | - - |
not provided Benign:3
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 30, 2024 | - - |
Benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Nov 01, 2024 | TUBB2B: BP4, BP7, BS1, BS2 - |
Likely benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at